185 related articles for article (PubMed ID: 32107408)
1. Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer's Disease.
Wong KH; Xie Y; Huang X; Kadota K; Yao XS; Yu Y; Chen X; Lu A; Yang Z
Sci Rep; 2020 Feb; 10(1):3654. PubMed ID: 32107408
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer's Diseases.
Wang X; Ho SL; Poon CY; Yan T; Li HW; Wong MS
Curr Alzheimer Res; 2019; 16(9):836-842. PubMed ID: 31453789
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
4. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.
Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A
ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
6. Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.
Martire S; Fuso A; Mosca L; Forte E; Correani V; Fontana M; Scarpa S; Maras B; d'Erme M
J Alzheimers Dis; 2016 Aug; 54(1):307-24. PubMed ID: 27567805
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for the treatment of Alzheimer's disease.
Gregori M; Masserini M; Mancini S
Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
9. Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice.
Batarseh YS; Bharate SS; Kumar V; Kumar A; Vishwakarma RA; Bharate SB; Kaddoumi A
ACS Chem Neurosci; 2017 Aug; 8(8):1756-1766. PubMed ID: 28471166
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein: a role in the export of amyloid-β in Alzheimer's disease?
Chai AB; Leung GKF; Callaghan R; Gelissen IC
FEBS J; 2020 Feb; 287(4):612-625. PubMed ID: 31750987
[TBL] [Abstract][Full Text] [Related]
11. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.
Raven F; Ward JF; Zoltowska KM; Wan Y; Bylykbashi E; Miller SJ; Shen X; Choi SH; Rynearson KD; Berezovska O; Wagner SL; Tanzi RE; Zhang C
EBioMedicine; 2017 Oct; 24():93-101. PubMed ID: 28919280
[TBL] [Abstract][Full Text] [Related]
12. Lack of support for bexarotene as a treatment for Alzheimer's disease.
O'Hare E; Jeggo R; Kim EM; Barbour B; Walczak JS; Palmer P; Lyons T; Page D; Hanna D; Meara JR; Spanswick D; Guo JP; McGeer EG; McGeer PL; Hobson P
Neuropharmacology; 2016 Jan; 100():124-30. PubMed ID: 26025659
[TBL] [Abstract][Full Text] [Related]
13. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
14. In vitro neuroprotective effects of naringenin nanoemulsion against β-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation.
Md S; Gan SY; Haw YH; Ho CL; Wong S; Choudhury H
Int J Biol Macromol; 2018 Oct; 118(Pt A):1211-1219. PubMed ID: 30001606
[TBL] [Abstract][Full Text] [Related]
15. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism.
Zhang J; Cao Q; Li S; Lu X; Zhao Y; Guan JS; Chen JC; Wu Q; Chen GQ
Biomaterials; 2013 Oct; 34(30):7552-62. PubMed ID: 23849878
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.
Elfakhri KH; Duong QV; Langley C; Depaula A; Mousa YM; Lebeouf T; Cain C; Kaddoumi A
Neuroscience; 2018 May; 379():269-280. PubMed ID: 29596966
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
[TBL] [Abstract][Full Text] [Related]
18. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
19. Developing Trojan horses to induce, diagnose and suppress Alzheimer's pathology.
Aziz AA; Amtul Z
Pharmacol Res; 2019 Nov; 149():104471. PubMed ID: 31590012
[TBL] [Abstract][Full Text] [Related]
20. A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice.
Zheng X; Pang X; Yang P; Wan X; Wei Y; Guo Q; Zhang Q; Jiang X
Acta Biomater; 2017 Feb; 49():388-401. PubMed ID: 27845275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
